MX2018000084A - Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. - Google Patents

Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.

Info

Publication number
MX2018000084A
MX2018000084A MX2018000084A MX2018000084A MX2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A MX 2018000084 A MX2018000084 A MX 2018000084A
Authority
MX
Mexico
Prior art keywords
composition containing
pharmaceutical composition
valsartan
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2018000084A
Other languages
English (en)
Other versions
MX380070B (es
Inventor
Seok Jung Yoon
Seon Lyu Chun
Oon Oh Tack
Kyun HAN Sung
Young Ryu Chae
Kyung Jeon Eun
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of MX2018000084A publication Critical patent/MX2018000084A/es
Publication of MX380070B publication Critical patent/MX380070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a una composición farmacéutica que comprende una primera composición que comprende amlodipino o una sal farmacéuticamente aceptable del mismo y valsartán o una sal farmacéuticamente aceptable del mismo; y una segunda composición que comprende rosuvastatina o una sal farmacéuticamente aceptable de la misma. La composición farmacéutica tiene excelente estabilidad y una velocidad de disolución alta. Mediante una combinación sinérgica de fármacos que tienen diferentes mecanismos, la composición farmacéutica puede aliviar los efectos secundarios de formulaciones individuales convencionales y, por lo tanto, se puede usar en mayor medida en la prevención y el tratamiento de enfermedades cardiovasculares, hipertensión, arteriosclerosis, hiperlipidemia y una enfermedad compleja de los mismos. La composición farmacéutica también mejora el cumplimiento de la medicación.
MX2018000084A 2015-07-08 2016-07-08 Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. MX380070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150097373 2015-07-08
PCT/KR2016/007464 WO2017007287A1 (ko) 2015-07-08 2016-07-08 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
MX2018000084A true MX2018000084A (es) 2018-03-22
MX380070B MX380070B (es) 2025-03-11

Family

ID=57685860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000084A MX380070B (es) 2015-07-08 2016-07-08 Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.

Country Status (8)

Country Link
EP (1) EP3320903B1 (es)
KR (1) KR101875112B1 (es)
ES (1) ES2882672T3 (es)
HU (1) HUE055181T2 (es)
MX (1) MX380070B (es)
PL (1) PL3320903T3 (es)
PT (1) PT3320903T (es)
WO (1) WO2017007287A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101920996B1 (ko) * 2017-04-26 2018-11-22 알보젠코리아 주식회사 HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제
KR102108396B1 (ko) * 2018-04-25 2020-05-07 제일약품주식회사 약학적 제제
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
MX2021010183A (es) * 2019-02-26 2021-09-21 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia.
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
MX2023002403A (es) * 2020-08-25 2023-03-22 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica en forma de dosificacion individual para tratar o prevenir hipertension e hipercolesterolemia.
CN112315926A (zh) * 2020-11-23 2021-02-05 常州制药厂有限公司 一种缬沙坦口服固体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
KR101207618B1 (ko) * 2008-02-22 2012-12-04 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
CN101637609A (zh) * 2009-09-06 2010-02-03 王丽燕 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物
SI2536396T1 (sl) * 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
KR101302243B1 (ko) * 2010-07-28 2013-09-02 씨제이제일제당 (주) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
KR101302306B1 (ko) * 2011-01-26 2013-09-03 씨제이제일제당 (주) 고지혈증 복합제
KR101446603B1 (ko) * 2011-11-22 2014-10-07 주식회사 인트로팜텍 텔미사르탄을 포함하는 단층정 복합 제제
US20160045497A1 (en) * 2013-03-12 2016-02-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CZ2013783A3 (cs) * 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
KR20150034120A (ko) * 2014-10-15 2015-04-02 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제

Also Published As

Publication number Publication date
KR101875112B1 (ko) 2018-07-09
EP3320903A4 (en) 2019-03-20
PL3320903T3 (pl) 2021-12-06
EP3320903B1 (en) 2021-05-19
PT3320903T (pt) 2021-08-19
HUE055181T2 (hu) 2021-11-29
WO2017007287A1 (ko) 2017-01-12
KR20170007695A (ko) 2017-01-19
MX380070B (es) 2025-03-11
ES2882672T3 (es) 2021-12-02
EP3320903A1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
JP2012193216A5 (es)
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201792591A1 (ru) Фармацевтические препараты
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
TN2019000063A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
HK1218861A1 (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈可分散的片剂形式的抗结核病的稳定的药物组合物及其制备方法
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
WO2020175922A3 (ko) 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물